Ravulizumab Antibody
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that binds with high affinity to complement protein C5, inhibiting terminal complement activation. It is applied in research models of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis, supporting both in vitro mechanistic studies and in vivo preclinical investigations.
Product Specifications
Product Name Alternative
Ravulizumab, ALXN 1210, ALXN1210, ALXN-1210, Complement System, Complement C5, ComplementSystem
UniProt
P01031
Target
Complement C5
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Immunology & Inflammation
Purity
>95% (May vary between batches)
Form
Liquid
Molecular Weight
145.80 kDa
Storage Conditions
Store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Tested Applications
ELISA, FC
Isotype
Human IgG2 kappa
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog